NO963984L - Nye, 1,4-disubstituerte piperidinderivater anvendbare som legemidler som virker på glutamatreseptorer - Google Patents

Nye, 1,4-disubstituerte piperidinderivater anvendbare som legemidler som virker på glutamatreseptorer

Info

Publication number
NO963984L
NO963984L NO963984A NO963984A NO963984L NO 963984 L NO963984 L NO 963984L NO 963984 A NO963984 A NO 963984A NO 963984 A NO963984 A NO 963984A NO 963984 L NO963984 L NO 963984L
Authority
NO
Norway
Prior art keywords
new
glutamate receptors
derivatives useful
piperidine derivatives
drugs acting
Prior art date
Application number
NO963984A
Other languages
English (en)
Other versions
NO963984D0 (no
Inventor
Dieter Seidelmann
Andreas Huth
Martin Kruger
Eckhard Ottow
Graham Jones Jones
Roland Neuhaus
Lechoslaw Turski
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of NO963984D0 publication Critical patent/NO963984D0/no
Publication of NO963984L publication Critical patent/NO963984L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Otolaryngology (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Det beskrives forbindelser med formel- I R1¿Z¿X¿N 0), så vel som fremstilling av dem og anvendelse av dem i legemidler.
NO963984A 1994-03-24 1996-09-23 Nye, 1,4-disubstituerte piperidinderivater anvendbare som legemidler som virker på glutamatreseptorer NO963984L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4410822A DE4410822A1 (de) 1994-03-24 1994-03-24 Neue Piperidin-Derivate
PCT/DE1995/000442 WO1995025721A1 (de) 1994-03-24 1995-03-23 Neue 1,4-disubstituierte piperidin-derivate als auf den glutamat-rezeptor wirkende arzneimittel

Publications (2)

Publication Number Publication Date
NO963984D0 NO963984D0 (no) 1996-09-23
NO963984L true NO963984L (no) 1996-09-23

Family

ID=6514110

Family Applications (1)

Application Number Title Priority Date Filing Date
NO963984A NO963984L (no) 1994-03-24 1996-09-23 Nye, 1,4-disubstituerte piperidinderivater anvendbare som legemidler som virker på glutamatreseptorer

Country Status (16)

Country Link
EP (1) EP0751936A1 (no)
JP (1) JPH09510460A (no)
KR (1) KR970701695A (no)
CN (1) CN1145618A (no)
AU (1) AU2212595A (no)
CA (1) CA2186010A1 (no)
CZ (1) CZ277096A3 (no)
DE (1) DE4410822A1 (no)
FI (1) FI963786L (no)
HU (1) HUT75653A (no)
IL (1) IL113103A0 (no)
NO (1) NO963984L (no)
PL (1) PL316382A1 (no)
SK (1) SK120196A3 (no)
WO (1) WO1995025721A1 (no)
ZA (1) ZA952431B (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9610741B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
ZA9610736B (en) * 1995-12-22 1997-06-27 Warner Lambert Co 2-Substituted piperidine analogs and their use as subtypeselective nmda receptor antagonists
ZA9610745B (en) * 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
CN1131031C (zh) * 1996-03-08 2003-12-17 弗·哈夫曼-拉罗切有限公司 作为nmda受体亚型阻断剂的4－苯基3，6－二氢－2h－吡啶基衍生物的应用
US5824662A (en) 1996-09-27 1998-10-20 Guilford Pharmaceuticals Inc. Treatment of global and focal ischemia using naaladase inhibitors
US6017903A (en) 1996-09-27 2000-01-25 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of treating a glutamate abnormality and effecting a neuronal activity in an animal using NAALADase inhibitors
CA2264043A1 (en) 1996-09-27 1998-04-02 Guilford Pharmaceuticals Inc. Naaladase compositions and methods for treating glutamate abnormality and effecting neuronal activity in animals
US6242450B1 (en) * 1998-07-27 2001-06-05 Eli Lilly And Company 5-HT1F antagonists
ES2221410T3 (es) * 1998-07-31 2004-12-16 Eli Lilly And Company Derivados heterociclil sulfamida.
AU4612300A (en) * 1999-05-13 2001-05-10 Shionogi & Co., Ltd. Preventive or therapeutic drugs for diabetes
TWI254043B (en) * 1999-06-08 2006-05-01 Hoffmann La Roche Ethanesulfonyl-piperidine derivatives having good affinity to N-methyl-D-aspartate (NMDA) receptor
ES2225330T3 (es) * 2000-03-22 2005-03-16 Hoffmann La Roche Compuesto de piperidina y piperacina para empleo en el tratamiento de alzheimer.
PE20020291A1 (es) 2000-08-21 2002-04-17 Hoffmann La Roche Profarmacos para ligandos del receptor nmda
US6770659B2 (en) * 2002-08-26 2004-08-03 Sk Corporation Benzoyl piperidine compounds
GB0224084D0 (en) 2002-10-16 2002-11-27 Glaxo Group Ltd Novel compounds
IL283725B2 (en) 2017-06-20 2024-04-01 Imbria Pharmaceuticals Inc Compositions and methods for increasing efficiency of cardiac metabolism
EP3866794B1 (en) 2018-10-17 2024-12-04 Imbria Pharmaceuticals, Inc. Methods of treating rheumatic diseases using trimetazidine-based compounds
EP3976101A4 (en) 2019-05-31 2023-06-21 Imbria Pharmaceuticals, Inc. FIBROSIS TREATMENT METHODS USING COMPOUNDS THAT PROMOTE GLUCOSE OXIDATION
CN110437136A (zh) * 2019-07-30 2019-11-12 东南大学 1-芳氧乙基哌啶-4-基苯甲酮衍生物及其制备方法和应用
US11530184B2 (en) 2020-06-30 2022-12-20 Imbria Pharmaceuticals, Inc. Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11780811B2 (en) 2020-06-30 2023-10-10 Imbria Pharmaceuticals, Inc. Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11883396B2 (en) 2021-05-03 2024-01-30 Imbria Pharmaceuticals, Inc. Methods of treating kidney conditions using modified forms of trimetazidine

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3576810A (en) * 1968-06-20 1971-04-27 Robins Co Inc A H 1-substituted-3-(-4)-aroylpiperidines
DE2827566A1 (de) * 1978-06-23 1980-01-10 Boehringer Mannheim Gmbh 1,2-dihydro-chinolin-2-on-derivate und verfahren zu ihrer herstellung
US4585774A (en) * 1981-05-08 1986-04-29 Otsuka Pharmaceutical Co., Ltd. Aniline derivatives and cardiotonic composition
PH19166A (en) * 1982-09-04 1986-01-16 Pfizer Dihydropyridined,pharmaceutical compositions and method of use
FR2534580A1 (fr) * 1982-10-13 1984-04-20 Synthelabo Derives de phenyl-1 piperidino-2 propanol, leur preparation, et medicaments qui les contiennent
DK623586A (da) * 1985-12-27 1987-06-28 Eisai Co Ltd Piperidinderivater eller salte deraf og farmaceutiske kompositioner indeholdende forbindelserne
US4868181A (en) * 1986-08-04 1989-09-19 E. I. Du Pont De Nemours And Company 1,4-dihydropyridine derivatives with calcium agonist and alpha1 -antagonist activity
KR910006138B1 (ko) * 1986-09-30 1991-08-16 에자이 가부시끼가이샤 환상아민 유도체
DE3888727T2 (de) * 1987-06-02 1994-09-01 Ajinomoto Kk Verwendung von Äthylamin-Derivaten als antihypertensive Wirkstoffe.
EP0424525B1 (en) * 1987-12-11 1994-12-21 Mitsui Petrochemical Industries, Ltd. Novel amines and their use
SU1731048A3 (ru) * 1988-05-27 1992-04-30 Эйсай Ко., Лтд (Фирма) Способ получени производных пиперидина или их фармацевтически приемлемых солей
FR2632641B1 (fr) * 1988-06-13 1990-10-12 Irceba ((aryl-4-piperazinyl-1)-2 ethoxy)-3 p-cymene, les derives ortho, meta, para monosubstitues ou disubstitues sur le noyau phenyle dudit produit, le procede de preparation desdits derives, et les medicaments contenant lesdits composes comme principe actif
US5153198A (en) * 1989-03-15 1992-10-06 Santen Pharmaceutical Co., Ltd. Agent for treatment of disorders of the cerebro-neural transmission system
US5116846A (en) * 1990-03-28 1992-05-26 Du Pont Merck Pharmaceutical Company N-aralkyl piperidine derivatives as psychotropic drugs
FR2681319B1 (fr) * 1991-09-12 1995-02-17 Synthelabo Derives de 1-(phenoxyalkyl)piperidine, leur preparation et leur application en therapeutique.
ES2060547B1 (es) * 1992-06-04 1995-06-16 Ferrer Int Mejoras en el objeto de la patente de invencion n/ 9201158 que se refiere a "procedimiento de obtencion de nuevos derivados de la 4-bencilpiperidina".
FR2705343B1 (fr) * 1993-05-17 1995-07-21 Fournier Ind & Sante Dérivés de beta,beta-diméthyl-4-pipéridineéthanamine, leur procédé de préparation et leur utilisation en thérapeutique.

Also Published As

Publication number Publication date
CA2186010A1 (en) 1995-09-28
AU2212595A (en) 1995-10-09
ZA952431B (en) 1995-12-19
WO1995025721A1 (de) 1995-09-28
MX9604201A (es) 1997-12-31
CN1145618A (zh) 1997-03-19
HUT75653A (en) 1997-05-28
DE4410822A1 (de) 1995-09-28
CZ277096A3 (en) 1997-01-15
EP0751936A1 (de) 1997-01-08
HU9602607D0 (en) 1996-11-28
IL113103A0 (en) 1995-06-29
NO963984D0 (no) 1996-09-23
KR970701695A (ko) 1997-04-12
FI963786A7 (fi) 1996-09-23
SK120196A3 (en) 1997-10-08
FI963786A0 (fi) 1996-09-23
FI963786L (fi) 1996-09-23
PL316382A1 (en) 1997-01-06
JPH09510460A (ja) 1997-10-21

Similar Documents

Publication Publication Date Title
NO963984L (no) Nye, 1,4-disubstituerte piperidinderivater anvendbare som legemidler som virker på glutamatreseptorer
ATE547416T1 (de) Pyrazolylbenzothiazolderivate und deren verwendung als therapeutische mittel
CY2488B1 (en) New 4-(oxyalkoxyphenyl)-3-oxy-piperidines for trea.
MY107740A (en) Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof
NO963053D0 (no) Kosmetiske eller farmasöytiske preparater inneholdende mangiferin eller derivater derav
DK0889876T3 (da) Meta-substituerede phenylensulfonamidderivater
DE69706407D1 (de) META-SUBSTITUIERTE PHENYLENDERIVATE UND IHRE VERWENDUNG ALS ALPHAvBETA3 INTERGRIN-ANTAGONISTEN ODER INHIBITOREN
MY119820A (en) Guanidine mimics as factor xa inhibitors
FI962418A0 (fi) Syklisiä amidijohdannaisia neurokiniini A antagonisteina
DE69604714D1 (de) Stilbenderivate und diese enthaltende pharmazeutische Zusammensetzungen
YU11997A (sh) Laktamski derivati i njihove farmaceutske kompozicije
ES2167463T3 (es) Componentes de un compuesto medicinal que comprenden derivados n-sustituidos de la o-toluidina y preparacion percutaneamente absorbible.
PT1007523E (pt) Derivados indole e 2,3-di-ridroindole, sua preparacao e utilizacao
PT650476E (pt) Agente vasodilatador periferico que contem derivados n-acilados de 4-amino-piperidina como ingredientes activos
NO20045486L (no) Nye forbindelser og deres anvendelse
EP0680328A1 (en) KETOCONAZOLE COMPOSITIONS FOR LOCAL USE.
ES2107284T3 (es) Nuevas n-piridil-carboxamidas, su procedimiento de preparacion y composiciones farmaceuticas que las contienen.
ES2156933T3 (es) Derivados triciclicos de benzazepina y benzotiazepina.
NO923721L (no) 4-desoksy-4-epipodophyllotoxin-derivat eller farmasoeytiskakseptabelt salt derav
IT1247974B (it) Derivati di piperidina, loro preparazione e uso
ES2153019T3 (es) Derivados de benzo-dioxano, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
NO972938L (no) Farmasöytiske piperazinforbindelser
RU94046387A (ru) Производные пиримидина, способ их получения, фармацевтическая композиция, ее применение и промежуточные продукты
HU9300202D0 (en) Benzo-pyrane derivatives, pharmaceutical preparatives containing them as active substance as well as method for producing them
EP0816366A4 (en) IMIDAZOTHIAZOLE COMPOUNDS